Latham & Watkins represented SLR Investment Corp. in the transaction. Vapotherm, Inc., a global medical technology company focused on the development and commercialization of non-invasive technologies...
Vapotherm’s $100 Million Debt Facility
ConsenSys’ $450 Million Series D Funding
Latham & Watkins represented ParaFi Capital in the transaction. ConsenSys closed a US$450 million financing round, bringing its valuation to over US$7 billion. ParaFi Capital led this...
SatixFy’s $813 Million Combination With Endurance Acquisition
Davis Polk and Gross & Co. advised SatixFy Communications Ltd. on the deal. Appleby and Morrison & Foerster acted for Endurance Acquisition Corp. Latham & Watkins...
Innocoll Biotherapeutics’ $125 Million Term Loan Facility
Latham & Watkins represented Innocoll Biotherapeutics in the transaction. Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, has announced the successful...
General Atlantic’s Investment in Chess.com
Latham & Watkins, Paul, Weiss, Herzog Fox & Neeman, Shartsis Friese, and Poultan & Yordan acted on the deal. Chess.com, the world’s largest chess platform, has...
Coherus BioSciences’ $300 Million Credit Financing with Pharmakon Advisors
Latham & Watkins represented Coherus in the transaction. Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) has entered into a loan agreement with investment funds managed...
Silver Spike Acquisition Corp. II’s $446 Million Combination With Eleusis
Davis Polk advised Silver Spike Acquisition Corp. II on the deal, while Latham & Watkins represented Eleusis. Silver Spike Acquisition Corp. II announced its approximately $446...
Arcutis Biotherapeutics’ $225 Million Non-Dilutive Debt Financing
Latham & Watkins represented Arcutis in the transaction. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that...
Mesoblast’s $90 Million Refinancing and Expansion of Senior Debt Facility
Latham & Watkins represented Mesoblast in the transaction. Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in stem cell medicines for inflammatory diseases, has announced that it has...
Arco Platform’s $150 Million Investment Round
Latham & Watkins represented Dragoneer in the transaction. Arco Platform Limited, or Arco (Nasdaq: ARCE), has entered into agreements led by affiliates of Dragoneer Investment Group LLC...
BridgeBio Pharma’s $750 Million Non-Dilutive Debt Financing
Latham & Watkins represented BridgeBio in the transaction. BridgeBio Pharma (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, executed a...
Tailwind Two Acquisition Corp.’s $1.58 Billion Combination with Terran Orbital Corporation
Kirkland & Ellis advised Tailwind Two and Akin Gump Strauss Hauer & Feld advised Terran Orbital on the deal. Latham & Watkins represented Francisco Partners. Tailwind...